NanoLithium® NP03 for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 May 2022: Trial started, NCT05423522
  2. 21 Jun 2022: Trial registered, NCT05423522

The trials

NCT05423522: Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

State
Completed
Phase
Phase 2
People
72 taking part
Started
20 May 2022
Primary completion
23 Jan 2024
Arms
NanoLithium® NP03
Results
None posted
  1. 20 May 2022: Trial started
  2. 21 Jun 2022: Trial registered
  3. 29 Oct 2024: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.